CD8A and cancer: Transgenic MSCs, transfected with interferon-alpha or interferon-beta, are engineered to exhibit different levels of anti-tumor efficacy.569 This strategy aims to combat tumors by enhancing apoptosis and enhancing the functions of NK cells and CD8+ T cells, thereby reinforcing the host’s immune response against cancer.570